Munafò Andrea Raffaele, Montalto Claudio, Franzino Marco, Pistelli Lorenzo, Di Bella Gianluca, Ferlini Marco, Leonardi Sergio, D'Ascenzo Fabrizio, Gragnano Felice, Oreglia Jacopo A, Oliva Fabrizio, Ortega-Paz Luis, Calabrò Paolo, Angiolillo Dominick J, Valgimigli Marco, Micari Antonio, Costa Francesco
Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
De Gasperis Cardio Center, Interventional Cardiology Unit, Niguarda Hospital, 20162 Milan, Italy.
Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14;9(8):709-721. doi: 10.1093/ehjcvp/pvad063.
To summarize the totality of evidence validating the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) score, ascertaining its aggregate discrimination and validation power in multiple population subsets.
We searched electronic databases from 2017 (PRECISE-DAPT proposal) up to March 2023 for studies that reported the occurrence of out-of-hospital bleedings according to the PRECISE-DAPT score in patients receiving DAPT following percutaneous coronary intervention (PCI). Pooled odds ratios (OR) with 95% confidence interval (CI) were used as summary statistics and were calculated using a random-effects model. Primary and secondary endpoints were the occurrence of any and major bleeding, respectively. A total of 21 studies and 67 283 patients were included; 24.7% of patients (N = 16 603) were at high bleeding risk (PRECISE-DAPT score ≥25), and when compared to those at low bleeding risk, they experienced a significantly higher rate of any out-of-hospital bleeding (OR: 2.71; 95% CI: 2.24-3.29; P-value <0.001) and major bleedings (OR: 3.51; 95% CI: 2.71-4.55; P-value <0.001). Pooling data on c-stat whenever available, the PRECISE-DAPT score showed a moderate discriminative power in predicting major bleeding events at 1 year (pooled c-stat: 0.71; 95% CI: 0.64-0.77).
This systematic review and meta-analysis confirms the external validity of the PRECISE-DAPT score in predicting out-of-hospital bleeding outcomes in patients on DAPT following PCI. The moderate discriminative ability highlights the need for future improved risk prediction tools in the field.
总结验证支架植入及后续双联抗血小板治疗患者出血并发症预测(PRECISE-DAPT)评分的全部证据,确定其在多人群亚组中的总体鉴别能力和验证效力。
我们检索了从2017年(PRECISE-DAPT提议)至2023年3月的电子数据库,以查找报告经皮冠状动脉介入治疗(PCI)后接受双联抗血小板治疗(DAPT)的患者根据PRECISE-DAPT评分发生院外出血情况的研究。采用95%置信区间(CI)的合并比值比(OR)作为汇总统计量,并使用随机效应模型进行计算。主要和次要终点分别为任何出血和大出血的发生情况。共纳入21项研究和67283例患者;24.7%的患者(N = 16603)出血风险高(PRECISE-DAPT评分≥25),与出血风险低的患者相比,他们发生任何院外出血的发生率显著更高(OR:2.71;95%CI:2.24 - 3.29;P值<0.001)以及大出血的发生率更高(OR:3.51;95%CI:2.71 - 4.55;P值<0.001)。在可行时汇总c统计量数据,PRECISE-DAPT评分在预测1年时的大出血事件方面显示出中等鉴别能力(合并c统计量:°0.71;95%CI:0.64 - 0.77)。
本系统评价和荟萃分析证实了PRECISE-DAPT评分在预测PCI后接受DAPT治疗患者院外出血结局方面的外部有效性。中等鉴别能力凸显了该领域未来改进风险预测工具的必要性。